Clinical Trial Update: A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study sponsored by Eli Lilly in patients with persistent or recurrent epithelial ovarian cancer or primary peritoneal carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED